These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 17854248)

  • 61. Efficacy and safety of 24-week pramipexole augmentation in patients with treatment resistant depression. A retrospective cohort study.
    Tundo A; Betro' S; Iommi M; de Filippis R
    Prog Neuropsychopharmacol Biol Psychiatry; 2022 Jan; 112():110425. PubMed ID: 34375683
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Pathological gambling associated with pramipexole use in Parkinson's disease].
    Lester J; Gonzalez-Aleman G; Zuniga-Ramirez C; Diaz-Pascuali SP; Raina-Castellino GB; Micheli-Gould F
    Rev Neurol; 2006 Sep 1-15; 43(5):316-8. PubMed ID: 16941434
    [No Abstract]   [Full Text] [Related]  

  • 63. Low dose pramipexole is neuroprotective in the MPTP mouse model of Parkinson's disease, and downregulates the dopamine transporter via the D3 receptor.
    Joyce JN; Woolsey C; Ryoo H; Borwege S; Hagner D
    BMC Biol; 2004 Oct; 2():22. PubMed ID: 15473914
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Pramipexole extended release in Parkinson's disease.
    Hametner EM; Seppi K; Poewe W
    Expert Rev Neurother; 2011 Sep; 11(9):1229-34. PubMed ID: 21864066
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Long-term use of pramipexole in the management of restless legs syndrome.
    Lipford MC; Silber MH
    Sleep Med; 2012 Dec; 13(10):1280-5. PubMed ID: 23036265
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Newer dopamine agonists in the treatment of restless legs syndrome.
    Weimerskirch PR; Ernst ME
    Ann Pharmacother; 2001 May; 35(5):627-30. PubMed ID: 11346069
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [The role of dopaminagonists in the treatment of Parkinson's disease].
    Ransmayr G
    Praxis (Bern 1994); 2005 Oct; 94(42):1633-8. PubMed ID: 16277084
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Efficacy and safety of pramipexole in Japanese patients with primary restless legs syndrome: A polysomnographic randomized, double-blind, placebo-controlled study.
    Inoue Y; Hirata K; Kuroda K; Fujita M; Shimizu T; Emura N; Uchimura N; Kagimura T; Sha K; Nozawa T
    Sleep Med; 2010 Jan; 11(1):11-6. PubMed ID: 19962941
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Double-blind, single-dose, cross-over study of the effects of pramipexole, pergolide, and placebo on rest tremor and UPDRS part III in Parkinson's disease.
    Navan P; Findley LJ; Jeffs JA; Pearce RK; Bain PG
    Mov Disord; 2003 Feb; 18(2):176-80. PubMed ID: 12539211
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Potential neuroprotection mechanisms in PD: focus on dopamine agonist pramipexole.
    Albrecht S; Buerger E
    Curr Med Res Opin; 2009 Dec; 25(12):2977-87. PubMed ID: 19842998
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Pramipexole (Mirapex) for restless legs syndrome.
    Med Lett Drugs Ther; 2007 Mar; 49(1257):26-8. PubMed ID: 17375031
    [No Abstract]   [Full Text] [Related]  

  • 72. Superior chronic tolerability of adjunctive modafinil compared to pramipexole in treatment-resistant bipolar disorder.
    Dell'osso B; Timtim S; Hooshmand F; Miller S; Wang PW; Hill SJ; Portillo N; Ketter TA
    J Affect Disord; 2013 Aug; 150(1):130-5. PubMed ID: 23261131
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Pramipexole Augmentation for Treatment-Resistant Unipolar and Bipolar Depression in the Real World: A Systematic Review and Meta-Analysis.
    Tundo A; Betro' S; de Filippis R; Marchetti F; Nacca D; Necci R; Iommi M
    Life (Basel); 2023 Apr; 13(4):. PubMed ID: 37109571
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Pramipexole safely replaces ergot dopamine agonists with either rapid or slow switching.
    Takahashi H; Nogawa S; Tachibana H; Kawamura J; Abe T; Ogino Y; Kashihara K; Hamada T; Kowa H;
    J Int Med Res; 2008; 36(1):106-14. PubMed ID: 18230274
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Treatment of juvenile Parkinson disease and the recurrent emergence of pathologic gambling.
    Garcia RF; Ordacgi L; Mendlowicz MV; de Freitas GR; Rosso AL; Nazar BP; Fontenelle LF
    Cogn Behav Neurol; 2007 Mar; 20(1):11-4. PubMed ID: 17356338
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Stealing as an Impulse Control Disorder Associated with Pramipexole - A Case Report from Forensic Psychiatric Practice].
    Clemm von Hohenberg C; Dreßing H
    Psychiatr Prax; 2017 Apr; 44(3):172-174. PubMed ID: 28399600
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease: an evidence-based comparison.
    Inzelberg R; Schechtman E; Nisipeanu P
    Drugs Aging; 2003; 20(11):847-55. PubMed ID: 12964891
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Hiccups and dopamine.
    Stegmeier-Petroianu A; Petroianu GA
    Am J Health Syst Pharm; 2008 Nov; 65(22):2092-4. PubMed ID: 18997134
    [No Abstract]   [Full Text] [Related]  

  • 79. Pramipexole: heart failure.
    Prescrire Int; 2013 Sep; 22(141):213. PubMed ID: 24171217
    [No Abstract]   [Full Text] [Related]  

  • 80. Impulsive and compulsive behaviors in Parkinson's disease.
    Evans AH; Strafella AP; Weintraub D; Stacy M
    Mov Disord; 2009 Aug; 24(11):1561-70. PubMed ID: 19526584
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.